Form 4: MYGN Chief Legal Officer Boosts Stake with RSU Grant

Myriad Genetics' Chief Legal Officer, Jennifer Lynne Fox, received a significant grant of restricted stock units and had shares withheld for tax obligations.

Summary

• Jennifer Lynne Fox, Chief Legal Officer of Myriad Genetics Inc. (MYGN), acquired 195,876 shares of common stock on March 12, 2026, through a grant of time-based restricted stock units (RSUs).
• These RSUs were granted under the company's 2017 Employee, Director and Consultant Equity Incentive Plan, with each RSU representing a contingent right to receive one share of common stock.
• The RSUs vest in three equal annual installments, commencing on the first anniversary of the grant date.
• On March 13, 2026, 5,995 shares of common stock were disposed of at a price of $4.66 per share to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.
• Following these transactions, Jennifer Lynne Fox directly beneficially owns 310,362 shares of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive alignment with shareholder interests through equity compensation, which is a standard and expected practice.

Positives

• The grant of 195,876 restricted stock units to the Chief Legal Officer indicates continued alignment of management's interests with shareholder value.
• The vesting schedule over three years suggests a long-term commitment from the executive.

Negatives

• The disposition of 5,995 shares, while for tax withholding, reduces the direct beneficial ownership slightly.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the granted restricted stock units.

Industry Context

StockSavvy.ai notes that executive stock grants, particularly restricted stock units with multi-year vesting schedules, are a standard practice in the biotechnology and diagnostics industry. These grants are designed to align executive incentives with long-term shareholder value creation, encouraging retention and performance. The tax withholding transaction is also a routine event associated with RSU vesting.

Comparison to Industry Standards

• StockSavvy.ai observes that the grant of RSUs to a Chief Legal Officer is consistent with executive compensation practices across the biotech sector, including companies like Illumina (ILMN) or Exact Sciences (EXAS), where equity compensation forms a significant part of total remuneration.
• The three-year vesting schedule is a common structure, similar to those seen in compensation plans at peers such as Guardant Health (GH) or Natera (NTRA), aiming to foster long-term commitment.
• The tax withholding at vesting is a standard operational procedure for equity compensation, mirroring practices observed globally.

Related Party Transactions

• The RSU grant is a transaction between the company and an executive, which is a form of related party transaction, but it is a standard compensation practice disclosed here.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Legal Officer's interests with shareholders, potentially encouraging long-term value creation. The tax withholding is a routine event with no direct negative impact on other shareholders.
• Employees: The filing highlights the company's use of its 2017 Employee, Director and Consultant Equity Incentive Plan, indicating a broader framework for employee equity compensation.

Next Steps

• The granted restricted stock units will vest in three equal annual installments, beginning on the first anniversary of the grant date (March 12, 2027).

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities (RSU grant and tax withholding) and does not present new information that would fundamentally alter the investment thesis for Myriad Genetics. It reinforces executive alignment but does not provide catalysts for significant price movement, thus a 'hold' recommendation is appropriate.

Keywords

Myriad Genetics, MYGN, Jennifer Lynne Fox, Chief Legal Officer, Restricted Stock Units, RSU Grant, Insider Trading, Executive Compensation, Stock Ownership, Form 4